Ann: Admedus enters distribution agreement for Spain, page-5

Admedus Limited (ASX:AHZ) is pleased to announce it has signed an exclusive distribution agreement with leading healthcare group, Cardiva, to market and supply its clinicallysuperior ADAPT® tissue products in Spain and Portugal. Under the agreement, Cardiva will initially distribute Admedus’ flagship ADAPT® tissue product CardioCel®, a non-calcifying, non-toxic bio-scaffold used to treat congenital heart defect and disease.

Additional ADAPT® products, VascuCel® and CardioCel 3D®, will be added to the Cardiva distribution portfolio later in the year. With a team of more than 120 professionals, Cardiva has been a leading company in the Spanish and Portuguese health system for nearly three decades - providing physicians access to a wide range of innovative devices in the areas of interventional cardiology, vascular and cardiac surgery and pain management.

Admedus Chief Operating Officer, David St Denis welcomed the new agreement, “Through this partnership with Cardiva, Admedus is thrilled to offer our clinically superior ADAPT® products to patients in Spain and Portugal - one of the five largest markets in Europe.” “Cardiva is a proven and highly-regarded healthcare company and this agreement represents another important milestone in Adremedus’ evolution as a leading medical technology company.” “With first orders due this month, we anticipate demand in this region to grow steadily as more surgeons are introduced to the unique clinical and health benefits of our ADAPT® technology,” he said.

Cardiva Director, Carlos Ibares Sanz, also welcomed today’s announcement, “Cardiva is excited to partner with Admedus, whose products and technology are at the forefront of cardiovascular science and bio-tissue engineering. This is an excellent opportunity for both Companies to reinforce their position as demonstrated leaders incardiovascular health and we look forward to introducing their unique ADAPT® products to the Spanish and Portuguese market.” The distribution agreement is effectively immediately.